Ascites retention during mogamulizumab treatment in a patient with adult T-cell leukemia/lymphoma

Takahiro Shima; Kenjiro Kamezaki; Kazuhiko Higashioka; Shuichiro Takashima; Goichi Yoshimoto; Koji Kato; Tsuyoshi Muta; Katsuto Takenaka; Hiromi Iwasaki; Toshihiro Miyamoto; Koichi Akashi

doi:10.2169/internalmedicine.55.5987

Ascites retention during mogamulizumab treatment in a patient with adult T-cell leukemia/lymphoma

Takahiro Shima, Kenjiro Kamezaki, Kazuhiko Higashioka, Shuichiro Takashima, Goichi Yoshimoto, Koji Kato, Tsuyoshi Muta, Katsuto Takenaka, Hiromi Iwasaki, Toshihiro Miyamoto, Koichi Akashi

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.

Original language	English
Pages (from-to)	1793-1796
Number of pages	4
Journal	Internal Medicine
Volume	55
Issue number	13
DOIs	https://doi.org/10.2169/internalmedicine.55.5987
Publication status	Published - 2016

All Science Journal Classification (ASJC) codes

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.55.5987

Cite this

@article{3f20b712ed1f40eaa036914326eece57,

title = "Ascites retention during mogamulizumab treatment in a patient with adult T-cell leukemia/lymphoma",

abstract = "A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.",

author = "Takahiro Shima and Kenjiro Kamezaki and Kazuhiko Higashioka and Shuichiro Takashima and Goichi Yoshimoto and Koji Kato and Tsuyoshi Muta and Katsuto Takenaka and Hiromi Iwasaki and Toshihiro Miyamoto and Koichi Akashi",

note = "Publisher Copyright: {\textcopyright} 2016 The Japanese Society of Internal Medicine.",

year = "2016",

doi = "10.2169/internalmedicine.55.5987",

language = "English",

volume = "55",

pages = "1793--1796",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "13",

}

TY - JOUR

T1 - Ascites retention during mogamulizumab treatment in a patient with adult T-cell leukemia/lymphoma

AU - Shima, Takahiro

AU - Kamezaki, Kenjiro

AU - Higashioka, Kazuhiko

AU - Takashima, Shuichiro

AU - Yoshimoto, Goichi

AU - Kato, Koji

AU - Muta, Tsuyoshi

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Miyamoto, Toshihiro

AU - Akashi, Koichi

PY - 2016

Y1 - 2016

N2 - A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.

AB - A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.

UR - http://www.scopus.com/inward/record.url?scp=84976570465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976570465&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.55.5987

DO - 10.2169/internalmedicine.55.5987

M3 - Article

C2 - 27374686

AN - SCOPUS:84976570465

SN - 0918-2918

VL - 55

SP - 1793

EP - 1796

JO - Internal Medicine

JF - Internal Medicine

IS - 13

ER -

Ascites retention during mogamulizumab treatment in a patient with adult T-cell leukemia/lymphoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this